Giant cell‐rich osteosarcoma: A match pair analysis of 11 new cases and literature review of 56 patients
Journal of Surgical Oncology · 2023
DOI: 10.1002/jso.27368 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Daniel Karczewski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Musculoskeletal Oncology Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, US…. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Background
Limited remains known on giant cell‐rich osteosarcoma (GCRO) with current studies being case reports or smaller series. This investigation compared GCRO and conventional osteoblastic osteosarcoma (OOS) with regard to demographics and survival.
Methods
An institutional tumor registry was used to identify 11 patients (six males) treated for GCRO. Mean age was 43 years. Staging showed American Joint Committee on Cancer (AJCC) stages IIA in four and IIB in seven patients. Mean follow‐up was 14 years. Study initiatives were: (1) Comparison of demographics between GCRO and 167 OOS from our institutional registry, (2) Differences in survival between GCRO and 33 OOS case controls (based on sex and AJCC stage), as well as 10 OOS using an age‐based propensity match, and (3) Summary of all GCRO cases reported in the literature.
Results
(1) Sex ( p = 0.53), grading ( p = 0.56), AJCC stage ( p = 0.42), and chemotherapeutic response rate ( p = 0.67) did not differ between groups. Age was significantly increased in GCRO ( p = 0.001). (2) Case–control and propensity‐matched groups revealed no difference in disease‐free survival, local recurrence, and distant disease‐free survival at 2 years ( p > 0.05). (3) Mean age of 56 patients (50% males) reported in the literature was 26 years. After merging with our 11 cases, the 2‐year disease‐free survival was 66%.
Conclusions
GCRO remains a rare disease with high short‐term mortality. Although affecting older patients more than conventional osteosarcoma, GCRO should not be viewed as a predictor of survival compared to OOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Musculoskeletal Oncology Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Orthopaedic Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Orthopedic Surgery, Musculoskeletal Oncology Service, Massachusetts General Brigham Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Orthopedic Surgery, Musculoskeletal Oncology Service, Boston Children's Hospital, Boston, Massachusetts, USA.
Zitieren
APA
Karczewski, D., Gonzalez, M. R., Bedi, A., Ready, J. E., Anderson, M. E., & Lozano-Calderon, S. A. (2023). Giant cell‐rich osteosarcoma: A match pair analysis of 11 new cases and literature review of 56 patients. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27368
Vancouver
Karczewski D, Gonzalez MR, Bedi A, Ready JE, Anderson ME, Lozano-Calderon SA. Giant cell‐rich osteosarcoma: A match pair analysis of 11 new cases and literature review of 56 patients. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27368
BibTeX
@article{Karczewski2023,
author = {Karczewski, Daniel and Gonzalez, Marcos R and Bedi, Angad and Ready, John E and Anderson, Megan E and Lozano-Calderon, Santiago A},
title = {Giant cell‐rich osteosarcoma: A match pair analysis of 11 new cases and literature review of 56 patients},
journal = {Journal of Surgical Oncology},
year = {2023},
doi = {10.1002/jso.27368}
}
EUVIMED